Recombinant Human Coagulation Factor Ⅷ
- Generic Name
- Recombinant Human Coagulation Factor Ⅷ
- Indication
用于血浆凝血因子Ⅷ（FⅧ）缺乏的甲型血友病（罕见病）治疗。在纠正或预防出血、急诊或择期手术中，本品起到暂时代替缺失的凝血因子的作用。
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Bioverativ Therapeutics Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT01181128
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
Phase 1
Completed
- Conditions
- Haemophilia ACongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00837356
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath